A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb’s Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
The Cancer Letter has covered—and will continue to cover—all the ways in which the current administration is fundamentally reshaping cancer research in the U.S. But this week, The Cancer Letter and the podcast focused on a patient story.
